Spyre Therapeutics reports strong Phase 2 data in IBD and HS, raises $400M, with cash runway into late 2029

Spyre Therapeutics announced positive Phase 2 trial results for its inflammatory bowel disease (IBD) monotherapies and a new hidradenitis suppurativa (HS) trial, showing promising clinical proof-of-concept. The company is advancing combination therapies with expected topline data in Q3 2027 and has raised over $400 million in October to fund pivotal HS programs. Despite some setbacks in rheumatic disease trials, Spyre maintains a strong cash position of $1.5 billion, supporting operations into the second half of 2029. These developments position Spyre to potentially transform treatment standards in immunology across multiple large markets.

Spyre Therapeutics shares are trading at USD 98.82 on Pluang as of Nov 04, 2026 04:11 WIB, reflecting a 3.47% increase in one day. The stock's market capitalization stands at $8.93 billion, indicating strong investor interest following the company's recent financial and clinical updates. Trading volume reached 752,066, showing active market participation in the health sector stock.